- Treatment options after sorafenib failure in patients with hepatocellular carcinoma
-
Dika IE, Abou-Alfa
- KMID: 2406033
- Clin Mol Hepatol.
- 2017 Dec;23(4):273-279.
- doi: 10.3350/cmh.2017.0108
Second line therapy after failure of sorafenib continues to be under study. Prognosis of hepatocellular carcinoma is measured in months, with median overall survival reaching 10.7 months with sorafenib. Because... -
- CITED
-
- Close
- SHARE
-
- Close
